Targeted Tissue Perfusion Versus Macrocirculatory-Guided Standard Care in Patients With Septic Shock: A Randomized Clinical Trial—The TARTARE-2S Trial
Primary resultResult — go to the resultDifference in medians 0.59 95% CI −3 to 4Authors' conclusion
In ICU patients with septic shock and lactate greater than 3 mmol/L, targeting tissue perfusion and allowing lower than recommended MAP did not increase the number of days alive with normal lactate and without vasopressor/inotropic drugs at 30 days.
Study context
- Population
- ICU patients with septic shock and blood lactate greater than 3 mmol/L194 analysed
- Participants
- 219 patients
- Comparison
- Targeted tissue perfusion vs mean arterial pressure (MAP)-guided standard care
- TTPn = 111
- Standard care (SC)n = 108reference
- Primary endpoint
- Days alive with normal lactate and without vasopressor/inotropic drugs
- Follow-up
- 30 days
Methodological detailsparallel-group, open-label, stratified allocation (trial site, chronic arterial hypertension), multicentre (3 European university hospital ICUs), Enrollment 2016 to 2022
- Parallel-group
- Open-label
- Stratified allocation (trial site, chronic arterial hypertension)
- Multicentre (3 European university hospital ICUs)
- Enrollment 2016 to 2022
Primary result
As reported in the abstract
Difference in medians
0.59
95% CI −3 to 4
By group
TTP vs SC
difference in medians 0.59 (95% CI −3 to 4)
Secondary outcomes
Mortality · day 30
Single components of primary outcome, days alive without organ support, mortality · 30 d
- Not significantly different between groups
MAP levels
- Lower in TTP vs SC
Safety
Serious adverse reactions
- Not significantly different between groups
Original publication
Targeted Tissue Perfusion Versus Macrocirculatory-Guided Standard Care in Patients With Septic Shock: A Randomized Clinical Trial—The TARTARE-2S Trial. Crit Care Med. Published 17 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →